Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-427 pembrolizumab monotherapy in advanced or metastatic renal cell carcinoma
2016-000589-47Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in renal cell carcinoma (RCC), clear cell renal cell carcinoma (ccRCC) and non-clear cell renal cell carcinoma (nccRCC), sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Jul 2016; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on 2016-000589-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000589-47.